Competitive Assay Patents (Class 435/7.93)
-
Patent number: 8110374Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.Type: GrantFiled: May 13, 2002Date of Patent: February 7, 2012Assignee: Cell Trend GmbHInventors: Kai Schulze-Forster, Harald Heidecke
-
Publication number: 20120009608Abstract: The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.Type: ApplicationFiled: July 8, 2010Publication date: January 12, 2012Applicants: AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO, HUMANITAS MIRASOLE S.p.A.Inventors: Barbara BOTTAZZI, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi
-
Publication number: 20120009211Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.Type: ApplicationFiled: March 31, 2011Publication date: January 12, 2012Applicant: TOPOTARGET SWITZERLAND SAInventors: JÜRG TSCHOPP, PASCAL SCHNEIDER, NILS HOLLER
-
Patent number: 8093066Abstract: A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.Type: GrantFiled: January 13, 2011Date of Patent: January 10, 2012Assignee: ImmuneTech, Inc.Inventors: Christopher R. Brown, James T. Murai
-
Patent number: 8093010Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: October 29, 2009Date of Patent: January 10, 2012Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 8088594Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.Type: GrantFiled: March 16, 2010Date of Patent: January 3, 2012Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
-
Patent number: 8088375Abstract: An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target.Type: GrantFiled: July 30, 2010Date of Patent: January 3, 2012Assignee: Epitomics, Inc.Inventors: Yaohuang Ke, Weimin Zhu, Guo-Liang Yu
-
Publication number: 20110318765Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.Type: ApplicationFiled: December 10, 2009Publication date: December 29, 2011Applicant: Sekisui Medical Co., Ltd.Inventors: Osamu Miyazaki, Syunsuke Kurashita, Kohei Takubo
-
Patent number: 8084223Abstract: Methods and reagents are disclosed for detecting a false result in an assay for determining a concentration of an analyte in a whole blood sample suspected of containing the analyte. The method comprises determining by means of the assay a concentration of the analyte utilizing a hemolyzed portion of the blood sample to obtain concentration value 1 and determining by means of the assay a concentration of the analyte utilizing a non-hemolyzed portion of the blood sample and multiplying the concentration times a hematocrit factor to obtain concentration value 2. A ratio of concentration value 1 divided by concentration value 2 is determined and is compared to a predetermined ratio of known reliability. If the ratio is less than the predetermined ratio, a false result is indicated.Type: GrantFiled: March 23, 2009Date of Patent: December 27, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventor: Tie Quan Wei
-
Patent number: 8084586Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.Type: GrantFiled: April 30, 2009Date of Patent: December 27, 2011Assignee: Saladax Biomedical, Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 8084224Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.Type: GrantFiled: April 5, 2010Date of Patent: December 27, 2011Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Publication number: 20110311989Abstract: Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified.Type: ApplicationFiled: December 10, 2009Publication date: December 22, 2011Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Osamu Miyazaki, Kohei Takubo, Syunsuke Kurashita
-
Publication number: 20110306070Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immuno sensor.Type: ApplicationFiled: June 14, 2010Publication date: December 15, 2011Applicant: ABBOTT POINT OF CARE INC.Inventors: John Lewis Emerson Campbell, Graham Davis
-
Patent number: 8076097Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.Type: GrantFiled: August 19, 2009Date of Patent: December 13, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov
-
Patent number: 8071317Abstract: Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties.Type: GrantFiled: February 14, 2011Date of Patent: December 6, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Tie Q. Wei, Alan Craig, Amy Posey
-
Patent number: 8063180Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.Type: GrantFiled: November 16, 2009Date of Patent: November 22, 2011Assignee: Seimens Healthcare Diagnostics Products GmbHInventors: Stefan Teigelkamp, Konrad Braun
-
Publication number: 20110275536Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.Type: ApplicationFiled: January 28, 2010Publication date: November 10, 2011Applicant: Pronota N.V.Inventor: Koen Kas
-
Patent number: 8053205Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.Type: GrantFiled: April 30, 2009Date of Patent: November 8, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Publication number: 20110269159Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.Type: ApplicationFiled: April 30, 2010Publication date: November 3, 2011Applicant: ABBOTT POINT OF CARE INC.Inventors: John Lewis Emerson Campbell, Graham Davis, John Emegbero Omakor, Adam Roger Moss, Ganesh Guhados
-
Patent number: 8043820Abstract: The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.Type: GrantFiled: November 7, 2008Date of Patent: October 25, 2011Assignee: The Regents of the University of CaliforniaInventors: David G. Amaral, Judy Van de Water
-
Publication number: 20110256147Abstract: Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the administration of a GD3 and GD3 inhibitors.Type: ApplicationFiled: December 1, 2009Publication date: October 20, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Mathias Oelke, Jonathan Schneck, Tonya Webb
-
Patent number: 8039220Abstract: Use of busulfan amide as stabilized standards in immunoassays for quantifying the amount of busulfan in samples of human biological fluids, methods for carrying out said immunoassay and kits for use in said immunoassay.Type: GrantFiled: September 17, 2008Date of Patent: October 18, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Yunying Li
-
Patent number: 8034631Abstract: A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.Type: GrantFiled: January 13, 2011Date of Patent: October 11, 2011Assignee: ImmuneTech, Inc.Inventors: Christopher R. Brown, James T. Murai
-
Publication number: 20110245342Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: ApplicationFiled: April 8, 2011Publication date: October 6, 2011Applicant: Bracco S.p.A.Inventors: Aldo PINCHERA, Ferruccio Santini, Giovanni Rivolta, Livio Cavalieri, Fulvia Vella, Federico Maisano
-
Patent number: 8030007Abstract: A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO: 6 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 6 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.Type: GrantFiled: March 3, 2011Date of Patent: October 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: A. Said El Shami, Bruce Campbell, Dennis Sustarsic, Niver Sahakian
-
Publication number: 20110223624Abstract: An immunoassay for screening a sample to detect the presence of ?-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed.Type: ApplicationFiled: July 2, 2009Publication date: September 15, 2011Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, James S. Metcalf, Geoffrey A. Codd
-
Patent number: 8012694Abstract: Antibodies for a variant of intact parathyroid hormone (PTH) or its fragments which have at position 17 the amino acid serine which is phosphorylated [p(17) PTH] and methods of producing the same. The invention further includes various immunoassay methods which use the described antibody alone or in combination with other antibodies to determine the circulating levels of p(17) intact PTH (1-84) or fragments thereof in biological fluids. Such antibodies and immunoassays can be used in conjunction with other antibodies to detect all biologically active forms of hPTH present in biological fluids.Type: GrantFiled: September 14, 2006Date of Patent: September 6, 2011Assignee: Immutopics, Inc.Inventors: Richard J. Zahradnik, Jeffrey R. Lavigne
-
Publication number: 20110212853Abstract: A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor.Type: ApplicationFiled: February 18, 2011Publication date: September 1, 2011Applicant: PROBIODRUG AGInventors: Holger Cynis, Martin Kleinschmidt, Kathrin Gans, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Nadine Taudte
-
Patent number: 8007767Abstract: Amino methyl imidazoles of Formula I are provided: wherein R, R1, R2, R3, R4, R5, and R6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.Type: GrantFiled: December 22, 2006Date of Patent: August 30, 2011Assignee: Novartis International Pharmaceutical Ltd.Inventors: Andrew Thurkauf, He Zhao, Suoming Zhang, Yang Gao
-
Patent number: 8008031Abstract: The present invention provides a method for detecting a beta-glucan having immunomodulatory activity in a human cell, which uses a test cell line that stably expresses human dectin-1 molecule on the cell surface and does not express other glucan receptors and a specific amount of a marker beta-glucan that specifically binds to human dectin-1 molecule for detection.Type: GrantFiled: December 19, 2007Date of Patent: August 30, 2011Assignee: National Pingtung University of Science and TechnologyInventors: Mei-Li Wu, Hso-Chi Chaung, Tzou-Chi Huang, Wen-Bin Chung, Hui-Ju Hung
-
Patent number: 8003337Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.Type: GrantFiled: July 20, 2009Date of Patent: August 23, 2011Assignees: Seikagaku Corporation, Saint Louis UniversityInventors: Kazuo Okamura, Shuichi Miyaura, Shunji Tomatsu
-
Patent number: 8003333Abstract: The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. A kit and methods of treating a subject having an organ transplant for ACR and treating an immune suppressed subject are also provided.Type: GrantFiled: September 22, 2008Date of Patent: August 23, 2011Assignee: MAYO Foundation for Medical Education and ResearchInventor: Michael R. Charlton
-
Patent number: 7998753Abstract: It is an object of the present invention to provide a measurement kit for developing a first developing solution and a second developing solution from different directions to suppress background noise, and an immunochromatography kit. The present invention provides a measurement kit, which comprises a first developing member for supplying a first developing solution and a second developing member for supplying a second developing solution, wherein the developing direction of the first developing solution is allowed to intersect with the developing direction of the second developing solution, so that development is carried out by developing the first and second developing solutions in different developing directions, and a water absorbent portion is established on the downstream of the developing directions.Type: GrantFiled: November 28, 2008Date of Patent: August 16, 2011Assignee: Fujifilm CorporationInventors: Hiroyuki Chiku, Junichi Katada, Hideyuki Karaki, Hiroki Terada
-
Patent number: 7993869Abstract: Provided is a mAb-based method for the detection of T cell stimulatory epitopes known to be involved in CD. The method has many advantages compared to the existing methods for the detection of gluten since it is the first method that can; (i) detect T cell stimulatory epitopes of gluten; (ii) detect the epitopes separately, (iii) detect T cell stimulatory epitopes present on gliadin and glutenin homologues present in other cereals also known to be involved in CD; and (iv) detect T cell stimulatory epitopes on both intact proteins and small protein fragments. The new method is a valuable tool in the screening of basic ingredients, semi manufactured ingredients and food products that are intended to be used in the gluten free diet of CD patients. Moreover the new method can also be used for the screening of cereals and different wheat varieties for the level of toxicity for CD patients.Type: GrantFiled: June 1, 2005Date of Patent: August 9, 2011Assignee: Academisch Ziekenhuis LeidenInventors: Jan Wouter Drijfhout, Frits Koning, Elisabeth Hermine Adriane Spaenij-Dekking
-
Patent number: 7994114Abstract: The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group consisting of hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils. In some embodiments, the activity can include the rate of multiplication of the cell or, where the cell is a quiescent cell, the binding can repress the activation of the quiescent cell. Other embodiments of the present invention are taught herein.Type: GrantFiled: March 29, 2006Date of Patent: August 9, 2011Assignee: British Canadian Biosciences CorpInventors: Ahmed Merzouk, Abdelkrim Habi, Donald Wong, Hassan Salari
-
Patent number: 7989217Abstract: The subject invention is an immunoassay for the semi-quantitative test kit for determination of human chrionic gonadtropin (hCG) in fluid sample (such as urine) as an aid in the diagnosis of a certain stage of pregnancy. The test device includes five strips having each having a dipping end or sample ends where sample can be applied. Results are indicated by coloration of two bands across a clear area of the strips, one band being coated with a reagent such as hCG antigens and the other with a reagent such as goat/rabbit polyclonal antibody gold conjugate. The combination of color indications on the bands provides the test results.Type: GrantFiled: March 29, 2007Date of Patent: August 2, 2011Assignee: AmeriTek USA, Inc.Inventors: Hsiao-Ching Yee, Kuo-Ching Yee, Hsian-Pei Yee
-
Publication number: 20110177537Abstract: The present invention provides diagnostic in vitro methods as well as kits and devices to be used in the methods of the present invention for diagnosis or prognosis of a pathologic condition characterized by the presence/absence of an endogenous hormone and/or hormone analog(s) thereof involved in diabetes or metabolic syndrome. The methods comprise a quantitative separation of at least those analytes of interest whose common presence interferes with measuring the presence/absence or concentration of one of the analytes of interest by a subsequent analytical method.Type: ApplicationFiled: April 29, 2009Publication date: July 21, 2011Applicant: BECTON, DICKINSON AND COMPANYInventors: Mikkel Nissum, Christoph Eckerskorn, Andreas Pfuetzner, Thomas Forst
-
Patent number: 7981598Abstract: It is intended to provide a compound inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same as one of the amino acid sequences represented by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and so on, or its salt; a compound inhibiting the expression of a gene of the above protein; an antisense nucleotide containing a base sequence which is complementary or substantially complementary to the base sequence of a DNA encoding the above protein or its partial peptide or a part of the base sequence; an antibody against the above protein or its partial peptide; and so on. The above compound, antisense nucleotide, antibody and so on are usable as a prophylactic/therapeutic agent for respiratory diseases, etc.Type: GrantFiled: March 25, 2005Date of Patent: July 19, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Masakazu Ichinose, Hiromasa Ogawa, Masafumi Tomaki, Yumiko Uno, Makoto Furusawa, Tatsumi Matsumoto
-
Patent number: 7981631Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.Type: GrantFiled: November 22, 2010Date of Patent: July 19, 2011Assignee: University of Florida Research FoundationInventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
-
Patent number: 7964370Abstract: An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are connected sequentially. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. An optical substrate and a substrate reagent including a saccharide oxidase are localized in the third region.Type: GrantFiled: October 17, 2008Date of Patent: June 21, 2011Assignee: Actherm IncInventors: Yi-Jen Wu, Wen-Pin Hsieh, Chih-Wei Hsieh
-
Patent number: 7951545Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.Type: GrantFiled: April 30, 2003Date of Patent: May 31, 2011Assignees: Seikagaku Corporation, Saint Louis UniversityInventors: Kazuo Okamura, Shuichi Miyaura, Shunji Tomatsu
-
Publication number: 20110124020Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.Type: ApplicationFiled: March 27, 2009Publication date: May 26, 2011Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
-
Patent number: 7947465Abstract: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies.Type: GrantFiled: August 7, 2008Date of Patent: May 24, 2011Assignee: Bio-Rad Laboratories, Inc.Inventors: William F. Link, Renato B. del Rosario, Randy V. Sweet, David L. King
-
Patent number: 7947439Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's tissue sample.Type: GrantFiled: October 20, 2008Date of Patent: May 24, 2011Assignees: Cornell Research Foundation, Inc., IDEXX Laboratories, Inc.Inventors: Roy Huchzermeier, Edward J. Dubovi
-
Patent number: 7947438Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's hair sample.Type: GrantFiled: July 7, 2008Date of Patent: May 24, 2011Assignees: Cornell Research Foundation, Inc., IDEXX LaboratoriesInventors: Roy Huchzermeier, Edward J. Dubovi
-
Patent number: 7943334Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.Type: GrantFiled: March 4, 2005Date of Patent: May 17, 2011Assignee: Prima Meat Packers, Ltd.Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Patent number: 7935497Abstract: A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay.Type: GrantFiled: February 23, 2007Date of Patent: May 3, 2011Assignee: Mologic LtdInventors: Paul James Davis, Mark James Davis, Mark Burnapp
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Publication number: 20110076703Abstract: A method of determining the concentration of at least one analyte in a plurality of samples by sequentially subjecting each sample to an analysis cycle comprises contacting the sample or a sample-derived solution with a sensor surface supporting a species capable of specifically binding the analyte or an analyte-binding species, detecting the amount of binding to the sensor surface, and regenerating the sensor surface to prepare it for the next analytical cycle, and based on the detected binding to the sensor surface determining the concentration of analyte in each sample using virtual calibration data calculated for each analysis cycle from real calibration data obtained by contacting the solid phase with samples containing known concentrations of analyte.Type: ApplicationFiled: June 1, 2009Publication date: March 31, 2011Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Peter Borg, Asa Frostell-Karlsson, Markku Hamalainen